Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

ABI-5366

Phase 1Small molecule

AAssembly Biosciences

ABI-5366 is one of 14 small molecule programs targeting Genital Herpes. It is currently in Phase 1.

1

Indications

1

Total Trials

1

Active Trials

13

Competitors

Pipeline

Status by Indication[3][1]

Indication

Genital HerpesActive, not recruiting

Genital HerpesPhase 1

Active, not recruiting

Competition

Competitive Landscape

31 competitors in Genital Herpes

#DrugCompanyPhaseTrials

Famvir

Zovirax

BBp Consulting, Inc

Valaciclovir

Valtrex

GGlaxo Dba Glaxosmithkline

Herpes Zoster Vaccine 1437173a

Aciclovir

ASP2151

Bexsero

AIC316

AAiCuris Anti-infective Cures AG

Matrix-M2

GGenocea Biosciences, Inc.

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Genital Herpes1 trial

A Study to Assess the Safety, Pharmacokinetics, and Antiviral Activity of ABI-5366 in Healthy Participants and Participants Seropositive for HSV-2 With Recurrent Genital Herpes

Active, not recruiting·AAssembly Biosciences·Phase 1·NCT06385327·115 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for ABI-5366. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ABI-5366 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ABI-5366. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Assembly Biosciences company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: AAssembly Biosciences

Related News